Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
BG-75202 features among several projects starting first-in-human trials.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
